



FÉDÉRATION INTERNATIONALE DES CONSEILS
EN PROPRIÉTÉ INTELLECTUELLE

INTERNATIONAL FEDERATION OF
INTELLECTUAL PROPERTY ATTORNEYS

INTERNATIONALE FÖDERATION
VON PATENTANWÄLTEN

FICPI WORLD CONGRESS



FÉDÉRATION INTERNATIONALE DES CONSEILS
EN PROPRIÉTÉ INTELLECTUELLE

INTERNATIONAL FEDERATION OF
INTELLECTUAL PROPERTY ATTORNEYS

INTERNATIONALE FÖDERATION
VON PATENTANWÄLTEN

PHARMACEUTICAL PATENT ISSUES



FÉDÉRATION INTERNATIONALE DES CONSEILS
EN PROPRIÉTÉ INTELLECTUELLE

INTERNATIONAL FEDERATION OF
INTELLECTUAL PROPERTY ATTORNEYS

INTERNATIONALE FÖDERATION
VON PATENTANWÄLTEN

PHARMACEUTICAL PATENT ISSUES

“Incremental” patent rights and “Evergreening”

Patent rights covering innovations on a patented API, such as new dosages, new combinations, new forms (i.e. polymorphs or enantiomers) or new methods of use.

Concerns have been raised that this strategy might be used to prolong patent protection in an inappropriate manner, creating a negative effects on access to medicines as well as on further innovation.



FÉDÉRATION INTERNATIONALE DES CONSEILS
EN PROPRIÉTÉ INTELLECTUELLE

INTERNATIONAL FEDERATION OF
INTELLECTUAL PROPERTY ATTORNEYS

INTERNATIONALE FÖDERATION
VON PATENTANWÄLTEN

PHARMACEUTICAL PATENT ISSUES

Several countries, mainly developing and least developed countries (such as India, Brazil but also Australia), have changed or are considering changing their laws or practices in order to prevent "evergreening".

"Incremental" patent rights may nevertheless confer new and inventive clinical improvements and therapeutic advantages.

May thus deserve patent protection.



FÉDÉRATION INTERNATIONALE DES CONSEILS
EN PROPRIÉTÉ INTELLECTUELLE

INTERNATIONAL FEDERATION OF
INTELLECTUAL PROPERTY ATTORNEYS

INTERNATIONALE FÖDERATION
VON PATENTANWÄLTEN

PHARMACEUTICAL PATENT ISSUES

Speakers selected to provide the audience with different, if not opposite, points of view and stimulate a discussion.

Are the concerns raised with respect to “evergreening” justified?

Is it possible to protect both the interests of patent holders and public health?



FÉDÉRATION INTERNATIONALE DES CONSEILS
EN PROPRIÉTÉ INTELLECTUELLE

INTERNATIONAL FEDERATION OF
INTELLECTUAL PROPERTY ATTORNEYS

INTERNATIONALE FÖDERATION
VON PATENTANWÄLTEN

PHARMACEUTICAL PATENT ISSUES

Moderator:

Roberto Pistolessi (IT)

Partner & CEO
European Patent Attorney

Dragotti & Associati

Dragotti
& Associati

international
IP attorneys





FÉDÉRATION INTERNATIONALE DES CONSEILS
EN PROPRIÉTÉ INTELLECTUELLE

INTERNATIONAL FEDERATION OF
INTELLECTUAL PROPERTY ATTORNEYS

INTERNATIONALE FÖDERATION
VON PATENTANWÄLTEN

PHARMACEUTICAL PATENT ISSUES

Speaker:

Jürgen Dressel PhD (DE)

Head Global Patent Litigation Strategy

Novartis Pharma AG





FÉDÉRATION INTERNATIONALE DES CONSEILS
EN PROPRIÉTÉ INTELLECTUELLE

INTERNATIONAL FEDERATION OF
INTELLECTUAL PROPERTY ATTORNEYS

INTERNATIONALE FÖDERATION
VON PATENTANWÄLTEN

PHARMACEUTICAL PATENT ISSUES

Speaker:

Fiona Bor PhD (UK)

Formerly at Teva and Mylan
(VP and IP Director)





FÉDÉRATION INTERNATIONALE DES CONSEILS
EN PROPRIÉTÉ INTELLECTUELLE

INTERNATIONAL FEDERATION OF
INTELLECTUAL PROPERTY ATTORNEYS

INTERNATIONALE FÖDERATION
VON PATENTANWÄLTEN

PHARMACEUTICAL PATENT ISSUES

Speaker:

Ellen F.M. 't Hoen (NL)

Lawyer and Independent Consultant

Founder of Medicines Patent Pool

1999-2009 @ Médecins sans Frontières'





FÉDÉRATION INTERNATIONALE DES CONSEILS
EN PROPRIÉTÉ INTELLECTUELLE

INTERNATIONAL FEDERATION OF
INTELLECTUAL PROPERTY ATTORNEYS

INTERNATIONALE FÖDERATION
VON PATENTANWÄLTEN

PHARMACEUTICAL PATENT ISSUES

Speaker:

Louis Harms (Justice)

Former Deputy President of the Supreme Court of
Appeal of SA; IP Professor @ University of Pretoria



University of Pretoria

14 April 2015

